Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

... and Merck shingles vaccine

June 5, 2006 | A version of this story appeared in Volume 84, Issue 23

FDA has cleared Merck & Co. to market the first vaccine for people 60 years old and older against shingles, a painful disease caused by reactivation of the virus that causes chicken pox. About half of the estimated 1 million cases of shingles that occur in the U.S. each year occur in the elderly, according to Merck. The Zostavax approval is more welcome news for the company, which is facing thousands of lawsuits as it struggles to recover from the recall of its blockbuster painkiller Vioxx. Earlier this month, an FDA advisory committee endorsed the effectiveness and safety of Gardasil, a Merck vaccine designed to prevent cervical cancer. And in February, the company won U.S. approval for RotaTeq, its vaccine against rotavirus, the most common cause of severe diarrhea in children.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.